ESPR - Company ID 0001434868
The table below shows Esperion Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$27.72M | -$22.63M | $53.83M | -$54.36M | -$38.99M | -$89.07M |
| Capital expenditure | $189.00K | $0.00 | $73.00K | $0.00 | - | $0.00 |
| Investing cash flow | -$189.00K | $0.00 | -$73.00K | $25.00M | -$18.10M | $0.00 |
| Dividends paid | - | - | - | - |
Esperion Therapeutics, Inc. reported operating cash flow of -$13.09M for fiscal year 2025. That is up 44.6% from -$23.65M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$47.73M (FY 2016) to -$13.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $16.22M | -$7.50M | $90.61M | $49.49M | -$1.44M | $2.04M |